
Lahey HCM Center. Trained @MidAmericaHeart via @BrownMedicine. Interested in health status, #HCM, methods and clinical trials.
Boston, MA
Joined December 2018
- Tweets356
- Following683
- Followers366
- Likes2.8K
Charles F. Sherrod IV, M.D., M.Sc. retweeted
What actually drives quality of life(QoL) in #HFrEF?Analysis of 2 HFrEF registries finds low KCCQ-QoL score is driven by symptoms &social limitations(effect size 0.48-0.60)less by physical limitations alone(effect size=0.34) Findings held across age & sex
ahajournals.org/doi/10.1161/…
Charles F. Sherrod IV, M.D., M.Sc. retweeted
Incredibly proud of this partnership between @Google & our faculty, led by Drs. @AdamRodmanMD, Mark Cohen, Jacob Koshy & Peter Brodeur, to test AMIE, Google’s patient facing conversational AI tool, in the first-of-its-kind, real world clinical study with primary care patients! ⬇️
Our medical research system, AMIE, is the first patient-facing conversational diagnostic tool of its kind to be studied prospectively in a real-world clinical setting.
In a study, published today in @TheLancet, we found that when patients chatted with AMIE before an in-person appointment, the interaction built their confidence and helped them organize their thoughts. And physicians who reviewed the information from the patient conversation got more time back to focus on collaborative care and shared decision-making instead of digging through data.
Charles F. Sherrod IV, M.D., M.Sc. retweeted
After a decade of growth, we’re now the Richard A. and Susan F. Smith Institute for Evidence, Innovation, and Policy.
The Institute's centers will bring together bold ideas, rigorous science, and clinical expertise to improve people’s health and lives.
bidmc.org/news-stories/all-n…
Acoramidis ⬆️ survival in #ATTR, but how do patients feel?
Read our 📄 in @JAMACardio!
Near 10-point KCCQ benefit, 2x more likely to be alive and stable (or even improved) with acoramidis.
Grateful for the mentorship @BrettSperryMD @MidAmericaHeart
jamanetwork.com/journals/jam…
What’s heartwarming about the state department making it difficult for certain nationalities to bring their families to the World Cup?
🚨 Heartwarming World Cup moment!
After Cape Verde keeper Vozinha’s heroic MOTM display (7 saves in the historic 0-0 vs Spain), the US State Department is stepping in to help bring his mother, Ana Candida Évora, to the tournament.
Visa and bond costs kept her away — now they’re actively assisting so she can watch her son live. ❤️🇨🇻
Secretary Marco Rubio urged officials to make it happen for the next match!
Thanks sharing! I hope to see more analyses integrating health status and survival to better explain the patient centered treatment benefits. #acoramidis #ATTR #KCCQ
Additional ATTRibute-CM analyses suggest acoramidis was associated with a greater likelihood of survival with preserved or improved KCCQ-defined health status over 30 months versus placebo.
Interesting integrated look from @CharlesFoxIV at survival and patient-reported outcomes in ATTR-CM.
#HeartFailure26 #MedIQESCHF26
1
269
Congrats to @MidAmericaHeart fellow Andrew Girard on this important publication! @BrettSperryMD @AndrewJSauer @stacyfarr
#HFpEF #KCCQ
New in JCF–I: Do echo changes in diastolic function reflect patient health status in HFpEF?
📉 In this TOPCAT sub-study of 211 patients, changes in echo parameters over 12 mo were not linked with KCCQ changes.
🔗 bit.ly/3JVsz1d
#HFpEF #PatientOutcomes #JCFIntersections
2
9
2,167
Congrats Omar!!
Presented today @crfheart #NYValves2025 on the potential application of patient-reported health status (KCCQ) after M-TEER or TAVR.🫀🔧
Special thanks to my mentors @chetanhuded @jspertus @suzannevarnold.
@saintlukeskc @MidAmericaHeart
📸See attached photo for key points.
2
387
Congrats, Omar! Great news for patients and great mentorship from @AndrewJSauer
At #ESCHF2025 🇷🇸 @MidAmericaHeart fellow Dr Omar Cantu-Martinez presents #CAREHKinHF real-world registry: >2,300 HF pts w/ hyperK risk with 9% on clinician selected patiromer.
Reduced severe HK and trend toward more optimal GDMT.
Take-home: early K⁺ control keeps GDMT on & protects heart + kidneys
Charles F. Sherrod IV, M.D., M.Sc. retweeted
Understanding patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM) is vital for managing treatment effectively.
We recently validated the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) in this population. Here’s why it matters:
A quick🧵
doi.org/10.1016/j.cardfail.2…
Charles F. Sherrod IV, M.D., M.Sc. retweeted
Congratulations TIARA Scholars implementing evidence into practice!
👏🏻
Today was the Certificate Ceremony & Keynote on the
“Future of Implementation Practice” with @AnneSales4 @HealthcareUMKC @FrontiersCTSI
🩺📖💕
👑
healthcareinstitute.umkc.edu…
Charles F. Sherrod IV, M.D., M.Sc. retweeted
📢 The Kansas City Cardiomyopathy Questionnaire (KCCQ-23) vs. NYHA Class in Obstructive Hypertrophic Cardiomyopathy
🔹 our brief report in @JCardFail explores how KCCQ-23 scores align with NYHA class in patients with obstructive hypertrophic cardiomyopathy (oHCM).
💡 Key Findings:
✅ KCCQ-23 scores inversely correlate with NYHA class but show wide variability within classes 📊
✅ Moving from NYHA III to II showed greater improvement in KCCQ scores than II to I 🔄
✅ Supports greater use of KCCQ-23 for precise patient-reported outcomes 🎯
🩺 These insights can help clinicians interpret KCCQ scores better for patients with oHCM
🔗 Read more:
onlinejcf.com/article/S1071-…
Charles F. Sherrod IV, M.D., M.Sc. retweeted
.@stephencookmd, et al., conducted a voluntary survey of #ACCFITs & #ACCEarlyCareer cardiologists to evaluate #LGBTQ+ representation, potential sources of mistreatment & measures of wellness among the cardiovascular workforce.
🔗 bit.ly/4gkTjms #ACCPride #JACCAdvances
Charles F. Sherrod IV, M.D., M.Sc. retweeted
We are excited to announce that the U.S. FDA approved our orally-administered near-complete (≥90%) stabilizer of TTR for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). We are proud of the opportunity to serve patients within this community. Learn more: bit.ly/3V5wVp4
Charles F. Sherrod IV, M.D., M.Sc. retweeted
Small mean treatment effects in heart failure trials may still lead to clinically meaningful improvements for a significant proportion of patients. #AHA24
ja.ma/3UOU52T
Congrats to @MAbdeljawadmd on this amazing study! @MidAmericaHeart
Just presented at #AHA24: Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire, from JAMA Cardiology, free to read online ja.ma/3YNd0MQ
Charles F. Sherrod IV, M.D., M.Sc. retweeted
In this study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) was a reliable and responsive measure of patient-reported health status in individuals with severe tricuspid regurgitation undergoing transcatheter tricuspid valve interventions. ja.ma/3NInl7x #TCT2024
Charles F. Sherrod IV, M.D., M.Sc. retweeted
An informative editorial by @MKIttlesonMD summarizing the background, context and findings from 4 studies in @JACCJournals from the #SEQUOIA #HCM trial
Great to see a whole issue of @JACCJournals dedicated to #HCM
jacc.org/doi/epdf/10.1016/j.…
#CardioTwitter
Charles F. Sherrod IV, M.D., M.Sc. retweeted
US Maternal Mortality is alarmingly high and cardiovascular conditions are lead cause.
❤️🩹🩺🤰🏻
Our @HealthcareUMKC investigators @DoFlorio @jspertus & Anna Grodzinsky have received the largest NIH grant in UMKC history to improve this.
‼️
Let’s go team!
🔥
umkc.edu/news/posts/2024/sep…
Congrats @DanNguyenCVO! @MidAmericaHeart
Novel strategies to accelerate adoption of evidence into practice & cut the 17 year implementation gap are paramount.
💡🫀🤓
Proud of our work to improve shared decision making for chronic coronary disease.
Kudos @DanNguyenCVO and team!
🙌🏻
ahajournals.org/doi/10.1161/…
2
182






































